Stay one step ahead. It takes more than just a single target
As the challenges you face evolve, stay one step ahead with the next generation quantitative HIV-1 assay with a dual target approach.
Rapidly mutating HIV-1 virus can evade quantification with a single target viral load assay. cobas® HIV-1 quantitative nucleic acid test for use on the cobas® 6800/8800 Systems targets two unique regions of the HIV-1 genome, gag and LTR, which are not subject to selective drug pressure. This approach improves test sensitivity, coverage and security in the event of mutation in one primer/probe region.
Features and Benefits
- Targeting two regions improves genotype inclusivity, detects HIV-1 variants and potentially avoids under quantification.
- Accurate quantification of HIV-1 RNA with a dual target assay contributes to optimal treatment decisions for patient management.
cobas® HIV-1 is an in vitro nucleic acid amplification test for the quantitation of HIV-1 in EDTA plasma of HIV-1-infected individuals.
This test is intended for use in conjunction with clinical presentation and other laboratory markers for the clinical management of HIV-1-infected patients. This test can be used for confirmation of HIV-1 infection in antibody reactive individuals and to assess patient prognosis by measuring the baseline HIV-1 level or to monitor the effects of antiretroviral therapy by measuring changes in HIV-1 RNA levels during the course of antiretroviral treatment.
Learn more at www.cobas68008800.com/assay_menu
cobas® 6800/8800 Systems are not available in all markets, including the U.S.